Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pl...
Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland
Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma ( Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland )
17 Sep 2021
OncoAlert and ecancer - ESMO 2021 preview
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 preview ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
17 Sep 2021
Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethaso...
Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain
Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ( Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain )
14 Sep 2021
Multidisciplinary management of ovarian germ cell tumours - a single institution...
Dr Sandip Ganguly - Tata Medical Center, Kolkata, India
Multidisciplinary management of ovarian germ cell tumours - a single institutional study from India ( Dr Sandip Ganguly - Tata Medical Center, Kolkata, India )
14 Sep 2021
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or car...
Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )
14 Sep 2021
Should every transplant eligible NDMM patient receive a transplant?
Prof Morie Gertz - Mayo Clinic, Rochester, USA
Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )
14 Sep 2021
Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients
Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, ...
Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )
10 Sep 2021
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-ta...
Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, ...
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )
10 Sep 2021
Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma patie...
Dr Jakub Radocha - Charles University, Hradec Kralove, Czech Republic
Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma patients ( Dr Jakub Radocha - Charles University, Hradec Kralove, Czech Republic )
10 Sep 2021
Idecabtagene vicleucel for relapsed and refractory multiple myeloma
Prof Larry Anderson - UT Southwestern Medical Center, Dallas, USA
Idecabtagene vicleucel for relapsed and refractory multiple myeloma ( Prof Larry Anderson - UT Southwestern Medical Center, Dallas, USA )
10 Sep 2021
OncoAlert and ecancer weekly round up for August 23rd - August 29th, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for August 23rd - August 29th, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
31 Aug 2021
Vaccinations in myeloma patients including for COVID-19
Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria
Vaccinations in myeloma patients including for COVID-19 ( Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria )
31 Aug 2021